- Aucune donnée
Français
- English
- 简体中文
- 繁体中文
- Français
- Русский
- Italiano
- 日本語
- 한국어
- Português
- Deutsch
- Español
- Türkçe
- Ελληνικά
- Nederlands
- Tiếng Việt
- Polski
Due to the surge in the deployment of small satellites, the increasing congestion of data transmission has always been a persistent problem in the aerospace industry. The collaboration between the Communication and Navigation Research Institute of the German Aerospace Center and Tesat Spacecom GmbH and Co. KG TESAT provides a powerful solution. They successfully developed and tested OSIRIS4CubeSat...
Recently, Marvel Fusion, a private German company dedicated to commercializing fusion energy through its own laser technology, announced that it has recently raised 62.8 million euros in Series B funding. This round of investors includes HV Capital, b2venture, Earlybird Venture Capital, Athos Venture, Primepulse, Plural Platform, and Deutsche Telekom. Meanwhile, Marvel Fusion has also received add...
The related paper was published in Heliyon under the title "A systematic review of Inconel 939 alloy parts development via additive manufacturing process".IN939 is a modern nickel based high-temperature alloy that can work continuously at high temperatures due to its excellent fatigue resistance, creep resistance, and corrosion resistance. The unique performance of IN939 is related to the composit...
The ATLAS R&D center is expected to be completed by mid-2026!A powerful new laser research facility located on the Foothills campus of Colorado State University will begin construction this month. The facility is planned to be put into use in mid-2026 and is the result of 40 years of laser development research at Colorado State University. It is a collaboration with the Fusion Energy Science P...
On July 3rd local time, Swiss ophthalmic care giant Alcon announced the acquisition of Israeli medical technology company Belkin Vision and its laser equipment assets for treating glaucoma.The transaction includes a prepayment of $81 million, of which approximately $65 million is in cash. In addition, if Alcon can establish this technology as the preferred first-line treatment option for clinical ...